Nancy Whiting Acquires 32,000 BOLD Shares
Nancy Whiting bought 32,000 shares of BOLD on June 15, 2026.
Key Points
- Nancy Whiting purchased 32,000 shares of BOLD on June 15, 2026, with no specified transaction price.
- BOLD shares traded at $1.41, with FMR LLC increasing its stake by 11,433 shares to a total of 2,695,455 shares.
- Analysts like HC Wainwright & Co. maintained a 'buy' rating with a $4 target as of August 11, 2025.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Nancy Whiting made a move by purchasing 32,000 shares of BOLD on June 15, 2026. The transaction did not specify a price, but it's a noteworthy addition to her portfolio.
Insider Buying and Selling at Boundless Bio, Inc.
On June 15, 2026, several insiders, including Nancy Whiting, bought shares of BOLD. Whiting acquired 32,000 shares, while other insiders like James Christensen and Jennifer Lew matched this purchase. Jonathan Lim bought 48,000 shares. Earlier in the year, on January 23, Zachary Hornby, President & CEO, added 600,000 shares, and David Hinkle, Senior VP of Finance, bought 140,000 shares.
Other Institutional Activity in BOLD
Institutional players have been active in BOLD as well. FMR LLC increased its holdings by 11,433 shares, bringing its total to 2,695,455 shares valued at about $2.97 million. Citadel Advisors LLC, however, trimmed its position by 11,773 shares, leaving it with 1,342,131 shares worth approximately $1.48 million. Stonepine Capital Management, LLC significantly reduced its stake by 112,389 shares, now holding 597,682 shares valued at $657,450. Meanwhile, Vanguard Capital Management LLC initiated a new position with 597,192 shares worth $656,911.
Boundless Bio, Inc. Stock Down 50.2%
Shares of BOLD recently traded around $1.41. The stock has seen varied activity with a 52-week range stretching from a low to a high that's not specified in the data provided. Investors watch these movements closely, especially given the recent insider and institutional activities.
$BOLD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have kept a keen eye on BOLD. On August 11, 2025, HC Wainwright & Co. maintained a 'buy' rating with a $4 price target. Earlier, on June 2, 2025, the firm initiated coverage with a 'buy' rating and a $5 target. Leerink Partners downgraded the stock to 'hold' with a $3 target on May 28, 2025, after initially setting a 'buy' rating at a much higher $25 target in April 2024.
Bottom Line
Nancy Whiting's recent purchase of BOLD shares is part of a broader pattern of insider buying, suggesting confidence in the company's prospects. Institutional adjustments highlight diverse strategies among major players. Investors will continue to monitor these developments, especially with analysts maintaining optimistic ratings. Remember, such insider and institutional activities are backward-looking and may not reflect current positions.
Get Boundless Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BOLD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.